Who are Inotuzumab ozogamicin (INO)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lumoxiti, INOTUZUMAB OZOGAMICIN, Besponsa, Besponsa, Besponsa, Inotuzumab ozogamicin-dose level 1.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/inotuzumab-ozogamicin-ino.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Inotuzumab ozogamicin (INO) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Inotuzumab ozogamicin (INO) (Inotuzumab ozogamicin (INO)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibody-drug conjugate (ADC). Area: Oncology.

marketed Antibody-drug conjugate (ADC) CD22 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Inotuzumab ozogamicin (INO) (Inotuzumab ozogamicin (INO)) — Charite University, Berlin, Germany. Inotuzumab ozogamicin is an anti-CD22 monoclonal antibody conjugated to a cytotoxic calicheamicin payload that binds to CD22 on B-cell lymphomas and delivers cell-killing toxin directly to tumor cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Inotuzumab ozogamicin (INO) TARGET	Inotuzumab ozogamicin (INO)	Charite University, Berlin, Germany	marketed	Antibody-drug conjugate (ADC)	CD22
Lumoxiti	MOXETUMOMAB PASUDOTOX	AstraZeneca	marketed		B-cell receptor CD22	2018-01-01
INOTUZUMAB OZOGAMICIN	INOTUZUMAB OZOGAMICIN		marketed	CD22-directed Immunoconjugate [EPC]	CD22	2017-01-01
Besponsa	inotuzumab	Pfizer	marketed	CD22-directed Immunoconjugate [EPC]	CD22	2017-01-01
Besponsa	inotuzumab-ozogamicin	Pfizer	marketed	Antibody-drug conjugate (ADC)	CD22	2017-01-01
Besponsa	Inotuzumab Ozogamicin	Pfizer Inc.	marketed	Antibody-drug conjugate (ADC)	CD22
Inotuzumab ozogamicin-dose level 1	Inotuzumab ozogamicin-dose level 1	Pfizer	marketed	Antibody-drug conjugate (ADC)	CD22

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibody-drug conjugate (ADC) class)

Pfizer · 3 drugs in this class
Jiaxing AnDiCon Biotech Co.,Ltd · 2 drugs in this class
AstraZeneca · 1 drug in this class
BioAtla, Inc. · 1 drug in this class
Byondis B.V. · 1 drug in this class
Charite University, Berlin, Germany · 1 drug in this class
Gustave Roussy, Cancer Campus, Grand Paris · 1 drug in this class
Medstar Health Research Institute · 1 drug in this class
OBI Pharma, Inc · 1 drug in this class
On Target Laboratories, LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Inotuzumab ozogamicin (INO) — Competitive Intelligence Brief. https://druglandscape.com/ci/inotuzumab-ozogamicin-ino. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab